PLoS ONE (Jan 2018)

Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study.

  • S Ali Husain,
  • Joshua Z Willey,
  • Yeseon Park Moon,
  • Mitchell S V Elkind,
  • Ralph L Sacco,
  • Myles Wolf,
  • Ken Cheung,
  • Clinton B Wright,
  • Sumit Mohan

DOI
https://doi.org/10.1371/journal.pone.0206839
Journal volume & issue
Vol. 13, no. 11
p. e0206839

Abstract

Read online

BACKGROUND:Accurate glomerular filtration rate estimation informs drug dosing and risk stratification. Body composition heterogeneity influences creatinine production and the precision of creatinine-based estimated glomerular filtration rate (eGFRcr) in the elderly. We compared chronic kidney disease (CKD) categorization using eGFRcr and cystatin C-based estimated GFR (eGFRcys) in an elderly, racially/ethnically diverse cohort to determine their concordance. METHODS:The Northern Manhattan Study (NOMAS) is a predominantly elderly, multi-ethnic cohort with a primary aim to study cardiovascular disease epidemiology. We included participants with concurrently measured creatinine and cystatin C. eGFRcr was calculated using the CKD-EPI 2009 equation. eGFRcys was calculated using the CKD-EPI 2012 equation. Logistic regression was used to estimate odds ratios and 95% confidence intervals of factors associated with reclassification from eGFRcr≥60ml/min/1.73m2 to eGFRcys65 years, obesity, current smoking, white race, and female sex. CONCLUSIONS:In a large, multiethnic, elderly cohort, we found a highly discrepant prevalence of CKD with eGFRcys versus eGFRcr. Determining the optimal method to estimate GFR in elderly populations needs urgent further study to improve risk stratification and drug dosing.